TrialNeuro-oncology2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Patrick Y Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.